In most cases of acromegaly, this excessive growth hormone production stems from a noncancerous tumor in the pituitary gland. However, in rarer instances, the disease can be triggered by tumors ...

The failure of facial or acral growth to progress beyond a certain point cannot be taken as evidence that the disease is quiescent. Indeed, the concept of "inactive" or "burnt-out" acromegaly ...

The novel consensus statement highlights current analytical pitfalls and the need to optimize disease control in acromegaly. Acromegaly is a serious endocrine disease associated with increased ...

Acromegaly is due to hypersecretion of growth ... Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

MAR002 holds promise as a first-in-class treatment for acromegaly, a life-shortening disease often with serious complications. We appreciate ProBioGen's support throughout the process and look forward ...

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

In about 80% of families the gene causing the disease is unknown. The pituitary tumour types occurring in these families are most commonly growth hormone-secreting adenomas (causing acromegaly or ...